Levosimendan reduces plasma amino terminal proBNP in patients with decompensated heart failure
- 10 October 2005
- journal article
- research article
- Published by Elsevier in International Journal of Cardiology
- Vol. 104 (3) , 355-356
- https://doi.org/10.1016/j.ijcard.2005.04.035
Abstract
No abstract availableThis publication has 5 references indexed in Scilit:
- Levosimendan reduces plasma B-type natriuretic peptide and interleukin 6, and improves central hemodynamics in severe heart failure patientsInternational Journal of Cardiology, 2005
- Time Course of B-Type Natriuretic Peptide (BNP) and N-Terminal ProBNP Changes in Patients with Decompensated Heart FailureClinical Chemistry, 2004
- Comparison of the Biomedica NT-proBNP Enzyme Immunoassay and the Roche NT-proBNP Chemiluminescence Immunoassay: Implications for the Prediction of Symptomatic and Asymptomatic Structural Heart DiseaseClinical Chemistry, 2003
- A rapid test for B-type natriuretic peptide correlates with falling wedge pressures in patients treated for decompensated heart failure: A pilot studyJournal of Cardiac Failure, 2001
- Efficacy and safety of intravenous levosimendan in severe low-output heart failure. A randomized, double-blind comparison to dobutamine (The LIDO-Study)Journal of Cardiac Failure, 1999